TLR4-independent and PKR-dependent interleukin 1 receptor antagonist expression upon LPS stimulation

Cellular Immunology

Volumn 259, Issue 1, 2009, Pages 33-40

  Na, Hye Young ^a   Mazumdar, Kaushiki ^a   Moon, Hye Jung ^a   Chang, Sooghee ^a   Seong, Seung Yong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

IL 1rn; LPS; PKR; Sepsis; TLR4

Indexed keywords

2 AMINOPURINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; PROTEIN KINASE R; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE IDENTIFICATION; IMMUNOBLOTTING; INNATE IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

2-AMINOPURINE; ANIMALS; CYTOKINES; DENDRITIC CELLS; EIF-2 KINASE; GENE EXPRESSION PROFILING; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LECTINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

BACTERIA (MICROORGANISMS);

EID: 68549132270     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.05.010     Document Type: Article

References (50)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29 (2001) 1303-1310
2. Medzhitov R., and Janeway Jr. C.A. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9 (1997) 4-9
3. Seong S.-Y., and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4 (2004) 469-478
4. Girardin E., Grau G.E., Dayer J.M., Roux-Lombard P., and Lambert P.H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319 (1988) 397-400
5. Hack C.E., De Groot E.R., Felt-Bersma R.J., Nuijens J.H., Strack Van Schijndel R.J., Eerenberg-Belmer A.J., Thijs L.G., and Aarden L.A. Increased plasma levels of interleukin-6 in sepsis. Blood 74 (1989) 1704-1710
6. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., and Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169 (1989) 333-338
7. Waage A., Espevik T., and Lamvik J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand. J. Immunol. 24 (1986) 739-743
8. Presterl E., Staudinger T., Pettermann M., Lassnigg A., Burgmann H., Winkler S., Frass M., and Graninger W. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am. J. Respir. Crit. Care Med. 156 (1997) 825-832
9. Heinzel F.P. The role of IFN-gamma in the pathology of experimental endotoxemia. J. Immunol. 145 (1990) 2920-2924
10. O'Grady N.P., Tropea M., Preas H.L., Reda D., Vandiveir R.W., Banks S.M., and Suffredini A.F. Detection of macrophage inflammatory protein (MIP)-1a and MIP-1b during experimental endotoxemia and human sepsis. J. Infect. Dis. 179 (1999) 136-141
11. Blackwell T.S., and Christman J.W. Sepsis and cytokines: current status. Br. J. Anaesth. 77 (1996) 110-117
12. Riedemann N.C., Guo R.-F., and Ward P.A. Novel strategies for the treatment of sepsis. Nat. Med. 9 (2003) 517-524
13. McIntyre K.W., Stepan G.J., Kolinsky K.D., Benjamin W.R., Plocinski J.M., Kaffka K.L., Campen C.A., Chizzonite R.A., and Kilian P.L. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med. 173 (1991) 931-939
14. Underhill D.M., and Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr. Opin. Immunol. 14 (2002) 103-110
15. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
16. Triantafilou M., and Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 23 (2002) 301-304
17. Manthey C.L., and Vogel S.N. Elimination of trace endotoxin protein from rough chemotype LPS. J. Endotoxin Res. 1 (1994) 84-91
18. Hirschfeld M., Ma Y., Weis J.H., Vogel S.N., and Weis J.J. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J. Immunol. 165 (2000) 618-622
19. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
20. Fitzgerald K.A., Rowe D.C., and Golenbock D.T. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 6 (2004) 1361-1367
21. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., Kitamura T., Kosugi A., Kimoto M., and Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3 (2002) 667-672
22. Carl V.S., Brown-Steinke K., Nicklin M.J., and Smith Jr. M.F. Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages. J. Biol. Chem. 277 (2002) 17448-17456
23. Malyak M., Guthridge J.M., Hance K.R., Dower S.K., Freed J.H., and Arend W.P. Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J. Immunol. 161 (1998) 1997-2003
24. Cabanski M., Steinmuller M., Marsh L.M., Surdziel E., Seeger W., and Lohmeyer J. PKR regulates TLR2/TLR4-dependent signaling in murine alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 38 (2008) 26-31
25. Williams B.R. Signal integration via PKR. Sci. STKE 2001 (2001) RE2
26. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., and Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25 (2000) 187-191
27. Eisenberg S.P., Evans R.J., Arend W.P., Verderber E., Brewer M.T., Hannum C.H., and Thompson R.C. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343 (1990) 341-346
28. Dripps D.J., Brandhuber B.J., Thompson R.C., and Eisenberg S.P. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J. Biol. Chem. 266 (1991) 10331-10336
29. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 77 (1991) 1627-1652
30. Haskill S., Martin G., Van Le L., Morris J., Peace A., Bigler C.F., Jaffe G.J., Hammerberg C., Sporn S.A., Fong S., et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc. Natl. Acad. Sci. USA 88 (1991) 3681-3685
31. Malyak M., Smith Jr. M.F., Abel A.A., Hance K.R., and Arend W.P. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J. Immunol. 161 (1998) 2004-2010
32. Gabay C., Gigley J., Sipe J., Arend W.P., and Fantuzzi G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur. J. Immunol. 31 (2001) 490-499
33. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
34. Arend W.P., Malyak M., Guthridge C.J., and Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16 (1998) 27-55
35. La E., and Fischer S.M. Transcriptional regulation of intracellular IL-1 receptor antagonist gene by IL-1 alpha in primary mouse keratinocytes. J. Immunol. 166 (2001) 6149-6155
36. Takada Y., Ichikawa H., Pataer A., Swisher S., and Aggarwal B.B. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene 26 (2007) 1201-1212
37. Goh K.C., deVeer M.J., and Williams B.R. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J. 19 (2000) 4292-4297
38. Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., and Williams B.R. Protein kinase R (PKR) interacts with and activates mitogen-activated protein kinase kinase 6 (MKK6) in response to double-stranded RNA stimulation. J. Biol. Chem. 279 (2004) 37670-37676
39. Gabay C., Dreyer M., Pellegrinelli N., Chicheportiche R., and Meier C.A. Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J. Clin. Endocrinol. Metab. 86 (2001) 783-791
40. Dreyer M.G., Juge-Aubry C.E., Gabay C., Lang U., Rohner-Jeanrenaud F., Dayer J.M., and Meier C.A. Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor kappa B/PU.1 binding site. Biochem. J. 370 (2003) 591-599
41. Hosoi T., Matsunami N., Nagahama T., Okuma Y., Ozawa K., Takizawa T., and Nomura Y. 2-Aminopurine inhibits leptin receptor signal transduction. Eur. J. Pharmacol. 553 (2006) 61-66
42. Gabay C., Smith M.F., Eidlen D., and Arend W.P. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J. Clin. Invest. 99 (1997) 2930-2940
43. Smith Jr. M.F., Carl V.S., Lodie T., and Fenton M.J. Secretory interleukin-1 receptor antagonist gene expression requires both a PU.1 and a novel composite NF-kappaB/PU.1/GA-binding protein binding site. J. Biol. Chem. 273 (1998) 24272-24279
44. La E., Rundhaug J.E., Pavone A., and Fischer S.M. Regulation of transcription of the intracellular interleukin-1 receptor antagonist gene by AP-1 in mouse carcinoma cells. Mol. Carcinog. 33 (2002) 237-243
45. Smith Jr. M.F., Eidlen D., Arend W.P., and Gutierrez-Hartmann A. LPS-induced expression of the human IL-1 receptor antagonist gene is controlled by multiple interacting promoter elements. J. Immunol. 153 (1994) 3584-3593
46. Kumar A., Haque J., Lacoste J., Hiscott J., and Williams B.R. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc. Natl. Acad. Sci. USA 91 (1994) 6288-6292
47. Patel R.C., and Sen G.C. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 17 (1998) 4379-4390
48. Ito T., Yang M., and May W.S. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J. Biol. Chem. 274 (1999) 15427-15432
49. Patel C.V., Handy I., Goldsmith T., and Patel R.C. PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. J. Biol. Chem. 275 (2000) 37993-37998
50. Ruvolo P.P., Gao F., Blalock W.L., Deng X., and May W.S. Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J. Biol. Chem. 276 (2001) 11754-11758